F2G Ltd Announces the Appointment of Dr Richard J. White as Chairman of the Board of Directors
F2G Limited, a Manchester UK based antifungal drug discovery and development company, announced the appointment of Dr Richard J. White as Chairman of the Company’s Board of Directors. Dr White has served as a non-executive director of F2G Ltd since April 2006.
F2G also announced the appointment of a new non-executive director, Dr Sten Verland of Sunstone Capital A/S.
"I congratulate Richard on his appointment as Chairman” said Shane M. Kelly, Chief Executive of F2G Ltd. “Richard has a wealth of experience in infectious disease drug discovery gained within Biotech and Pharma. He has been a tremendous asset to the Company during his time on the Board and I look forward to working with him towards the further development of F2G Ltd. The Board also welcomes Dr Sten Verland, whose proven expertise in building successful businesses will be a valuable addition to the team.”
Dr Richard J. White commented ”This an exciting time for F2G as our lead program progresses to clinical testing and I eagerly anticipate working closely with the other Board members".
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
